Show Notes
This episode is brought to you by Semafor Healthcare.Delivered weekly from David Lim,
Semafor Healthcare connects the dots between decisions in government, business, and technology to reveal how they impact the future of healthcare. Each edition will provide the analysis you need to understand and stay ahead of a rapidly changing landscape.
Subscribe for free.
Health Affairs This Week
is on a break this week. Today, we are publishing an episode from A Health Podyssey
, where Health Affairs
Editor-in-Chief Alan Weil brings you in-depth conversations with leading researchers and influencers shaping the big ideas in health policy and the health care industry. Health Affairs This Week
will return next week.
Subscribe to
A Health Podyssey:
RSS |
Apple Podcasts |
Spotify |
Stitcher |
Google Podcasts The United States is facing a drug affordability crisis.
Even as we celebrate scientific discovery, the health benefits of drugs are limited due to barriers of affordability, often even for people with health insurance. The RAND Corporation reports that on average drug prices in the United States are more than two and a half times those in 32 other nations studied. The disparities are even wider when we focus just on brand name drugs.
Drug pricing is the subject of seemingly perennial debates. One side focuses on access barriers due to high prices while the other side argues that lower prices threaten future innovation.
Stacie Dusetzina from Vanderbilt University Medical Center joins A Health Podyssey to talk about the complex world of drug pricing.